Keywords: ShK C-terminal amide Potassium channel Electrophysiology Potential of mean force Umbrella sampling a b s t r a c t ShK, a 35-residue peptide from a sea anemone, is a potent blocker of potassium channels. Here we describe a new ShK analogue with an additional C-terminus Lys residue and amide. ShK-K-amide is a potent blocker of Kv1.3 and, in contrast to ShK and ShK-amide, is selective for Kv1.3. To understand this selectivity, we created complexes of ShK-K-amide with Kv1.3 and Kv1.1 using docking and molecular dynamics simulations, then performed umbrella sampling simulations to construct the potential of mean force of the ligand and calculate the corresponding binding free energy for the most stable configuration. The results agree well with experimental data.
Introduction
The voltage-gated potassium channel Kv1.3 is significantly upregulated in activated effector memory (T EM ) cells in humans [1, 2] . As a consequence, Kv1.3 blockers constitute valuable new therapeutic leads for the treatment of autoimmune diseases mediated by T EM cells, such as multiple sclerosis and rheumatoid arthritis [1] [2] [3] [4] .
ShK toxin, a 35-residue peptide from the sea anemone Stichodactyla helianthus [5, 6] , is a potent blocker of potassium channels. Its solution structure ( Fig. 1 ) has been determined [7, 8] and the surface involved in binding to Kv channels has been mapped using alanine scanning and synthetic analogues [9] [10] [11] . The essential residues are clustered on a surface of the peptide that binds to a shallow vestibule at the outer entrance to the ion conduction pathway and blocks the entrance to the pore, with Lys22 of ShK projecting into and occluding the ion conduction pathway [12] [13] [14] .
ShK blocks not only Kv1.3 (K d 11 pM) but also Kv1.1 (K d 16 pM), Kv1.7 [12] and Kv3.2 channels [15, 16] . As this lack of specificity constitutes a potential drawback for the use of ShK as a therapeutic agent [4] , a considerable effort has been devoted to developing ShK analogues that are selective for Kv1.3 over Kv1.1 and other potassium channels. More selective analogues have been created by the incorporation of non-natural amino acids or adducts, including ShK-Dap22, in which Lys22 was replaced by the positively-charged, non-natural residue 1,3-diaminopropionic acid (Dap) [12] , ShK-F6CA, a fluorescein-labelled analogue of ShK [17] , and analogues with either phospho-Tyr (ShK-186) or phosphonoPhe (ShK-192) attached via a hydrophilic linker to Arg1 [15, 18] . However, these analogues have several potential limitations, for example, ShK-186 and ShK-192 contain non-protein adducts and the phosphorylated residue of ShK-186 is susceptible to hydrolysis. As a result, there is still scope for the development of new analogues with enhanced stability and increased specificity for Kv1. 3 .
In this study we describe a new analogue of ShK modified at the C-terminus (Fig. 1 ) by addition of a Lys residue and amide.
ShK-K-amide proves to be a potent and selective blocker of Kv1.3, in contrast to ShK and ShK-amide, both of which lack selectivity for Kv1.3. In an effort to understand the molecular basis for this selectivity, we have created complexes of this peptide with Kv1.3 and Kv1.1 channels using docking and molecular dynamics (MD) simulations. Umbrella sampling simulations were then performed to construct the potential of mean force (PMF) of the ligand and calculate the corresponding binding free energy for the most stable configuration [19] .
Materials and methods

Peptide synthesis
ShK-K-amide was synthesized on a Prelude peptide synthesizer using an Fmoc-tBu strategy. The peptide was synthesized starting with Rink amide resin (Peptides International, Louisville, KY). All couplings were mediated with diisopropyl carbodiimide and 6-chloro-hydroxybenzotriazole. Following solid-phase assembly of the linear peptide chain, the peptide was cleaved from the solid support and simultaneously deprotected using Reagent K for 2 h at room temperature. The crude peptide was precipitated into ice cold diethyl ether and washed thoroughly to remove cationic scavengers from the cleavage cocktail, dissolved in 50% aqueous acetic acid, then diluted in water and the pH adjusted to 8.0 with NH 4 OH. Disulfide bond formation was facilitated with reduced and oxidized glutathione according to previously used protocols for ShK [9] .
The progress of folding was followed by RP-HPLC using a Phenomenex Luna C18 column using a gradient of acetonitrile versus H 2 O containing 0.05% TFA from 10-70% over 35 min. Folding of the three disulfide bonds was also confirmed by the loss of 6 mass units from the crude material as determined by ESI-MS.
Modelling and docking
Here we give a brief description of the computational methods and refer to the Supplementary data and [19, 20] for details. The structure of ShK-K-amide was generated from that of ShK [7] using the mutator plugin in the VMD software [21] . For the Kv1.1 and Kv1.3 structures, we used the homology models developed in [19] . The initial poses for the Kv1.x-ShK-K-amide complexes were found using the docking program HADDOCK [22] , and then refined . The backbone and three disulfide bridges (Cys3-Cys35, Cys12-Cys28 and Cys17-Cys32) are shown for the closest-to-average solution structure [7] . in MD simulations. The most stable complex in each case was further run for 20 ns to check equilibration and for data analysis. MD simulations were performed using the NAMD program [23] with the CHARMM22 force field [24] including the CMAP correction [25] . The PMF of each toxin was determined from the umbrella sampling MD simulations using the weighted histogram analysis method [19, 26] .
Cells and cell lines
L929 mouse fibroblast cells stably expressing mKv1.1 and mKv1.3 channels [27] were gifts from Dr. K. George Chandy (University of California, Irvine). They were maintained in DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 100 IU/ml penicillin, 0.1 lg/ml streptomycin, 2 mM L-glutamine, 10% heatinactivated fetal bovine serum, and 0.5 mg/ml G418 (EMD Chemicals, Gibbstown, NJ).
Freshly prepared buffy coats were purchased from the Gulf Coast Regional Blood Center (Houston, TX) under a protocol approved by the Baylor College of Medicine Institutional Review Board. Mononuclear cells were isolated from the buffy coats using Histopaque-1077 gradients (Sigma, St Louis, MI) and used immediately.
Electrophysiological analysis
Experiments were conducted at room temperature in the whole-cell configuration of the patch-clamp technique. A manual setup and an automated Port-a-patch setup (Nanion, North Brunswick, NJ) were used in parallel, both linked to a HEKA EPC10USB amplifier. The patch pipettes or chips had a resistance of 2-4 MX when filled with an internal solution containing (in mM): 145 KF, 10 HEPES, 10 EGTA, and 2 MgCl 2 , pH 7.2, 290 mOsm. The bath solution contained (in mM): 160 NaCl, 4.5 KCl, 2 CaCl 2 , 1 MgCl 2 , 10 HEPES, pH 7.2, 300 mOsm. Kv currents were elicited every 30 s by 200-ms depolarizing pulses from a holding potential of À80 mV to 40 mV. K d values and Hill coefficients were determined by fitting the Hill equation to the reduction of peak current measured at 40 mV.
T lymphocyte proliferation assays
Proliferation assays were conducted as described previously [15] . Briefly, mononuclear cells (10 5 /well) were plated into 96-well plates and pre-incubated with the peptide blockers for 30 min at 37°C in RPMI medium (Invitrogen) supplemented with 100 IU/ml penicillin, 0.1 lg/ml streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, 1% non-essential amino acids, 1% RPMI vitamins, 50 lM b-mercaptoethanol, and 1% heat-inactivated fetal bovine serum. T lymphocyte activation and proliferation was induced by the addition of 40 ng/ml anti-CD3 antibodies (Clone OKT3, eBioscience, San Diego, CA). Cells were cultured for 72 h at 37°C, 5% CO 2 , and [ 
Results
Peptide synthesis
The desire to modify ShK at a site distant from its key pharmacophore led us to consider the C-terminus (Fig. 1) . We therefore added a C-terminal Lys amide to the native sequence as this Lys would be located outside the Cys3-Cys35 disulfide loop and should not interfere with peptide folding. Amidation was included to enhance resistance to exoproteases. The peptide was assembled using standard Fmoc-tBu solid-phase peptide synthesis. The crude product was oxidized using the glutathione-mediated oxidative folding conditions that have been used successfully for many other ShK analogues [9] . As shown in Fig. 2A , the peptide folded rapidly, resulting in the typical pattern of a major earlier-eluting peak by RP-HPLC followed by later-eluting misfolded and side-product species. ShK-K-amide was purified to homogeneity by preparative RP-HPLC, as shown in Fig. 2B . The peptide had the correct mass by ESI-MS (data not shown), demonstrating that the three disulfide bonds had been formed. The yield was 16% of theory based upon the starting resin.
Potency and selectivity of potassium channel blockade
We used patch-clamp electrophysiology to determine the potency and selectivity of ShK and ShK-K-amide on Kv1.3 and Kv1.1 channels (Fig. 3A, B) . As described previously [12, 28] , ShK inhibited Kv1.3 and Kv1.1 channels with similar potencies (IC 50 of 9 ± 2 pM for Kv1.3 and 23 ± 3 pM for Kv1.1). ShK-K amide retained a high affinity for the Kv1.3 channels (IC 50 26 ± 3 pM) but displayed a much lower affinity for Kv1.1 channels (IC 50 942 ± 120 pM) resulting in a 36-fold selectivity for Kv1.3 over Kv1.1 channels. As a control for the contribution of the C-terminal amidation of ShK in this increase in selectivity of ShK-K-amide, we determined the potency of ShK-amide on both channels and found that the C-terminal amidation did not affect the selectivity of the peptide, with IC 50 values of 35 ± 5 pM on Kv1.3 and 37 ± 4 pM on Kv1.1 channels.
Inhibitory effects on human T lymphocyte proliferation
Kv1.3 channel blockers are potent inhibitors of the proliferation of human T lymphocytes. ShK-K-amide inhibited the proliferation of freshly-isolated human T cells with a similar potency (IC 50 % 3 nM) to that of ShK and its well-characterized analogue ShK-186 (Fig. 3C) [1,2,28,29] . Addition of an amidated Lys to the C-terminus of ShK changes the total charge at the C-terminus from negative to positive. This has a major effect on the N-terminus and the Arg1 side chain in ShK-K-amide as they are pushed away from the C-terminus and become free to engage with channel residues (Fig. 4) . In ShK, the N-terminus and Arg1 side chain are attracted to the C-terminus, which neutralizes their charges to a degree and prevents their association with channel residues. Inspection of the contact distances for the Kv1.3-ShK and Kv1.3-ShK-K-amide complexes (Table 1) and their evolution as ShK-K-amide is pulled out (Fig. S1) shows that Arg1 becomes the dominant residue in binding of this analogue. Contrasting the binding modes of ShK and ShK-K-amide (Table 1) , it is seen that Arg1 is already involved in binding of ShK to Kv1.3 so the mutation leads to some rearrangement among the contact pairs but their number and quality as measured by the contact distances are preserved. In contrast, Arg1 is not involved in binding of ShK to Kv1.1 so the C-terminal extension causes a major disruption in the binding mode. In particular, Lys18 points away from the channel and Arg29 is no longer coupled to any negatively charged residues (Table 1 ; Fig. 4 ). The loss of these two charge contacts, which play an important role in binding of ShK, is not compensated by addition of Arg1 to the contact list (Table 1 ; Fig. 4) . From the evolution of the contact distances (Fig. S1 ), one can also identify another strongly coupled pair (Arg29-Ser379) in Kv1.3-ShK-K-amide that has no counterpart in Kv1.1-ShK-Kamide and thus contributes to the higher affinity of this analogue for Kv1.3.
These observations imply that the binding affinity of ShK-Kamide for Kv1.1 should decrease relative to ShK while no such change is expected for Kv1.3. To confirm these expectations, we have computed the PMFs for dissociation of ShK-K-amide from the Kv1.1 and Kv1.3 channels. Details of the umbrella sampling MD simulations and convergence studies of the PMFs are provided in the Supplementary data (Fig. S2) . Comparison of the ShK-Kamide PMFs with those of ShK (Fig. 5) shows that indeed the affinity of ShK-K-amide for Kv1.1 is reduced substantially compared to that of ShK, while they are essentially the same for Kv1.3. The standard binding free energies obtained from the PMF's are compared to the experimental values in Table. 2. All the calculated binding free energies agree with the experimental values within 1 kcal/mol which is the chemical accuracy of the calculations. In particular, the C-terminal extension is predicted to cause a 2.5 kcal/mol increase in the binding free energy of the toxin for Kv1.1, which is in good agreement with the experimental value of 2.2 kcal/mol.
Discussion
ShK-K-amide blocks Kv1.3 with an IC 50 of 26 ± 3 pM, similar to the affinities for this channel of ShK (9 ± 2 pM) [12, 28] and ShK-amide (35 ± 5 pM). However, with an IC 50 of 942 ± 120 pM for Kv1.1, ShK-K-amide is far more selective for Kv1.3 over Kv1.1 than ShK, which blocks Kv1.1 with an IC 50 of 23 ± 3 pM [12, 28] , or ShK-amide (37 ± 4 pM). This is the first report of an ShK analogue with enhanced Kv1.3 selectivity following modification Table 1 Comparison of the strongly interacting residues in ShK and ShK-K-amide complexes with Kv1.1 and Kv1.3. The average atom-atom distances obtained from the MD simulations are listed in columns 3 and 6 (in units of Å). Subscripts refer to the side chain atoms and the monomer identity is indicated in parenthesis. of the C-terminus; all prior work that resulted in an increase in selectivity had focused on either the pore-blocking Lys22 or the N-terminus of ShK [3, 4] . As selectivity for Kv1.3 over Kv1.1 is an important criterion for potential therapeutic applications in the treatment of autoimmune disease in humans [3, 4] , our results suggest that analogues with this C-terminal extension may be useful platforms for further modification. Our results also provide an excellent example of the application of MD simulations and umbrella sampling PMF calculations [19] to rationalize the effects of changes in ShK on its binding affinity for various potassium channels. ShK has almost the same affinity for Kv1.1 as for Kv1.3 but its binding modes for the two channels are distinct. This provides a strategy for designing ShK analogues that are selective for Kv1.3 in which ShK is modified so as to perturb the binding mode for Kv1.1 but not Kv1.3. As shown here, ShK-K-amide provides a nice example of this strategy. In general, any C-terminal extension that results in release of the N-terminal should yield a similar selectivity for Kv1.3 over Kv1.1.
